Otsuka To Host Web Briefing on Tolvaptan Phase 3 Trial Results In Polycystic Kidney Disease

(Tokyo, Japan and Princeton, N.J.) – Otsuka Pharmaceutical Co., Ltd. (OPCJ) and its affiliate Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) are pleased to invite investors and media to a November 4 web briefing on in-depth results from the REPRISE phase 3 trial for tolvaptan, a drug candidate for the treatment of patients in the U.S. with autosomal dominant polycystic kidney disease (ADPKD). Webinar briefing for investors and media on November 4 at 7 PM, US Central Daylight Time Agenda Welcome, introductions and overview (5 min.) Robert McQuade, Ph.D., executive vice president/chief strategic officer, OPDC About ADPKD and Tolvaptan (15 min.) Frank Czerwiec, M.D., Ph.D., vice president, Global Clinical Development, OPDC REPRISE phase 3 data (20 min.) Ronald Perrone, M.D., scientific director, Clinical and Translational Research Center and associate chief, Division of Nephrology, Tufts Medical Center, Boston, MA, and a member of the Phase 3 REPRISE trial Steering Committee Q&A (20 min.) To participate in the web briefing, kindly pre-register at: http://event.on24.com/wcc/r/1534382-1/77E66445B009CE3491DBB035504DCF69 Confirmation of registration and information on how to access the web briefing on November 4 will be sent to registrants by email. An archived version of the webcast will be accessible on the website of Otsuka Pharmaceutical Company’s parent company, Otsuka Holdings Co., Ltd., within 24 hours after the web briefing. The REPRISE phase 3 trial data will also be presented earlier in the day on November 4 in a late breaking oral abstract session at American Society of Nephrology (ASN) Kidney Week 2017, in New Orleans (Abstract# SA-OR128). Attendees of Kidney Week 2017 are invited to attend the session, between 10:30 AM and 12:30 PM in Hall J. The REPRISE trial was completed to supply confirmatory data to the previous study[i] to address the Complete Response Letter issued by the U.S. FDA in 2013 for a New Drug Application for tolvaptan in the treatment of adults with ADPKD. About Tolvaptan Tolvaptan is a selective vasopressin V2-receptor antagonist. By selectively blocking vasopressin at the V2-receptor, tolvaptan has been shown to decrease cyst-cell proliferation and fluid secretion in subjects with ADPKD, ultimately reducing cyst development.[ii] In a previous Phase 3 clinical trial, tolvaptan was associated with reduced kidney growth and slowed decline of kidney function.[i] About Otsuka Otsuka Pharmaceutical Company is a global healthcare company with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” All Otsuka stories start by taking the road less travelled. Learn more about Otsuka at www.otsuka.co.jp/en/ and connect with us in the US on LinkedIn and Twitter at @OtsukaUS. Contacts for media Otsuka in Japan Jeffrey Gilbert (Outside the US)Leader, Pharmaceutical PR Otsuka Pharmaceutical, Co., Ltd. [email protected] Phone: +81 3 6361 7379 Otsuka in the US Jill RomanDirector, External Communications,Otsuka America Pharmaceutical, Inc. [email protected] Phone: +1 (609) 524-6788 Otsuka and Lundbeck will initiate a third Phase 3 trial to evaluate brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type Next article We defy limitation, so that others can too. Follow us LinkedIn Facebook X Instagram Threads YouTube Footer Links California Supply Chains Act Returned Goods Authorized Distributor of Record Terms and Conditions OAPI and OPDC Privacy Policy Anthem Transparency in Coverage OAPI and OPDC Locations 508 Carnegie Center Dr,Princeton, NJ 08540, United States Phone 609-524-6788 2440 Research Blvd,Rockville, MD 20850, United States Phone 301-424-9055 3956 Point Eden WayHayward, CA 94545, United States Phone 800-562-3974 © 2025 Otsuka America Pharmaceutical, Inc All rights reserved. June 2024 01US24EXC0009 Otsuka's affiliated companies around the world work with a shared commitment to contribute to better health worldwide. Otsuka Global Site Japan Asia, The Middle East& Oceania Australia China Egypt Indonesia Pakistan Philippines South Korea Taiwan Thailand Vietnam North &South America Brazil Canada US Europe EU Denmark Finland France Germany Italy Norway Spain Sweden Switzerland UK Search

The release as fetched from its publisher. otsuka-us.com ↗